Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer’s disease patients
- 6 November 2015
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 233 (4) , 591-598
Abstract
Rationale The G-protein-coupled relaxin family receptors RXFP1 and RXFP3 are widely expressed in the cortex and are involved in stress responses and memory and emotional processing. However, the identification of these receptors in human cortex and their status in Alzheimer’s disease (AD), which is characterized by both cognitive impairments and neuropsychiatric behaviours, have not been reported. Objectives In this study, we characterized RXFP receptors for immunoblotting and measured RXFP1 and RXFP3 immunoreactivities in the postmortem neocortex of AD patients longitudinally assessed for depressive symptoms. Methods RXFP1 and RXFP3 antibodies were characterized by immunoblotting with lysates from transfected HEK cells and preadsorption with RXFP3 peptides. Also, postmortem neocortical tissues from behaviourally assessed AD and age-matched controls were processed for immunoblotting with RXFP1 and RXFP3 antibodies. Results Compared to controls, putative RXFP1 immunoreactivity was reduced in parietal cortex of non-depressed AD patients but unchanged in depressed patients. Furthermore, putative RXFP3 immunoreactivity was increased only in depressed AD patients. RXFP1 levels in the parietal cortex also correlated with severity of depression symptoms. In contrast, RXFP1 and RXFP3 levels did not correlate with dementia severity or β-amyloid burden. Conclusion Alterations of RXFP1 and RXFP3 may be neurochemical markers of depression in AD, and relaxin family receptors warrant further preclinical investigations as possible therapeutic targets for neuropsychiatric symptoms in dementia.Keywords
Funding Information
- Biomedical Research Council of Singapore (BMRC10/21/19/645)
- National Medical Research Council (NMRC/CSA/032/2011, NMRC/IRG/1287/2011)
This publication has 46 references indexed in Scilit:
- Tau phosphorylation in human brain: relationship to behavioral disturbance in dementiaNeurobiology of Aging, 2012
- Relaxin-3-Deficient Mice Showed Slight Alteration in Anxiety-Related BehaviorFrontiers in Behavioral Neuroscience, 2011
- Neurochemical basis for symptomatic treatment of Alzheimer's diseaseNeuropharmacology, 2010
- Sertraline for the Treatment of Depression in Alzheimer DiseaseThe American Journal of Geriatric Psychiatry, 2010
- The CRF system, stress, depression and anxiety—insights from human genetic studiesMolecular Psychiatry, 2009
- Relaxin Family Peptide Receptors – former orphans reunite with their parent ligands to activate multiple signalling pathwaysBritish Journal of Pharmacology, 2007
- Relaxin-3: Improved Synthesis Strategy and Demonstration of Its High-Affinity Interaction with the Relaxin Receptor LGR7 BothIn VitroandIn VivoBiochemistry, 2005
- Neurons expressing relaxin 3/INSL 7 in the nucleus incertus respond to stressEuropean Journal of Neuroscience, 2005
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- The patients dying after long terminal phase have acidotic brains; implications for biochemical measurements on autopsy tissueJournal of Neural Transmission, 1985